STOCK TITAN

Artivion Inc - AORT STOCK NEWS

Welcome to our dedicated news page for Artivion (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Artivion's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Artivion's position in the market.

Rhea-AI Summary
Artivion, Inc. (NYSE: AORT) announced its financial results for Q3 2023. The company achieved revenue of $87.9 million, a 14% increase on a GAAP basis and 12% increase on a non-GAAP constant currency basis compared to Q3 2022. Non-GAAP adjusted EBITDA increased 34% to $13.9 million. Aortic stent graft revenues increased 30% and On-X revenues increased 14% compared to Q3 2022. The company is nearing completion of enrollment in the PERSEVERE clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.88%
Tags
-
Rhea-AI Summary
Artivion, Inc. to release third quarter 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.97%
Tags
-
Rhea-AI Summary
Artivion announces positive results from On-X Aortic Heart Valve study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.71%
Tags
none
Rhea-AI Summary
Interim data shows significant reduction in all-cause mortality with AMDS
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.71%
Tags
none
-
Rhea-AI Summary
Artivion, Inc. to present at Deutsche Bank conference on October 3, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
conferences
-
Rhea-AI Summary
Artivion, Inc. to present at Gilmartin Group Emerging Growth Company Showcase on September 21, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
conferences acquisition
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
-
Rhea-AI Summary
Artivion, Inc. (NYSE: AORT) will participate in three upcoming investor conferences. They will present at the Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023, and participate in investor meetings at the Needham Virtual MedTech & Diagnostics 1x1 Conference on August 14, 2023, and the UBS MedTech, Tools, and Genomics Summit on August 16, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
none
Artivion Inc

NYSE:AORT

AORT Rankings

AORT Stock Data

847.13M
34.32M
5.46%
86.87%
6.81%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Kennesaw

About AORT

cryolife, headquartered in georgia, is a leader in the processing and distribution of human tissues for use in cardiac and vascular surgeries. cryolife using its proprietary synergraft® technology processes the cryovalve® sg pulmonary heart valve and cryopatch® sg pulmonary cardiac patch. cryolife’s bioglue® surgical adhesive is approved in the u.s. for use as an adjunct to sutures and staples to help control bleeding, ce marked in the european community, approved in canada and australia for use in soft tissue repair, and in japan for use in the repair of aortic dissections. cryolife’s cardiogenesis specializes in the treatment of severe angina using a laser console system and fiber-optic handpieces to perform a surgical procedure known as transmyocardial revascularization (tmr). cryolife markets the hero® graft, which provides vascular access for hemodialysis patients. cryolife distributes perclot®, an absorbable powdered hemostat, in international markets. cryolife’s biofoam® surgica